Micro–Positron Emission Tomography/Contrast-Enhanced Computed Tomography Imaging of Orthotopic Pancreatic Tumor–Bearing Mice Using the α v β 3 Integrin Tracer 64 Cu-Labeled Cyclam-RAFT-c(-RGDfK-) 4

Abstract

The purpose of this study was to develop a clinically relevant orthotopic xenotransplantation model of pancreatic cancer and to perform a preclinical evaluation of a new positron emission tomography (PET) imaging probe, ⁶⁴Cu-labeled cyclam-RAFT-c(-RGDfK-)₄ peptide (⁶⁴Cu-RAFT-RGD), using this model. Varying degrees of α_vβ₃ integrin expression in several human pancreatic cancer cell lines were examined by flow cytometry and Western blotting. The cell line BxPC-3, which is stably transfected with a red fluorescence protein (RFP), was used for surgical orthotopic implantation. Orthotopic xenograft was established in the pancreas of recipient nude mice. An in vivo probe biodistribution and receptor blocking study, preclinical PET imaging coregistered with contrast-enhanced computed tomography (CECT) comparing ⁶⁴Cu-RAFT-RGD and ¹⁸F-fluoro-2-deoxy-D-glucose (¹⁸F-FDG) accumulation in tumor, postimaging autoradiography, and histologic and immunohistochemical examinations were done. Biodistribution evaluation with a blocking study confirmed that efficient binding of probe to tumor is highly α_vβ₃ integrin specific. ⁶⁴Cu-RAFT-RGD PET combined with CECT provided for precise and easy detection of cancer lesions. Autoradiography, histologic, and immunohistochemical examinations confirmed the accumulation of ⁶⁴Cu-RAFT-RGD in tumor versus nontumor tissues. In comparative PET studies, ⁶⁴Cu-RAFT-RGD accumulation provided better tumor contrast to background than ¹⁸F-FDG. Our results suggest that ⁶⁴Cu-RAFT-RGD PET imaging is potentially applicable for the diagnosis of α_vβ₃ integrin–expressing pancreatic tumors.

PANCREATIC CANCER has the worst prognosis among malignant solid tumors. It is one of the leading causes of cancer-related mortality across the world, with an incidence almost equaling mortality.¹ The 5-year survival rate is still as low as 6% according to the American Cancer Society 2012 statistics.² Providing early diagnosis and efficient therapeutic measures remains a major challenge, and suitable animal models that mimic the clinical situation as closely as possible are essential for developing and comparing new diagnostic and therapeutic strategies.³ There are presently two main types of human xenograft mouse models used for pancreatic cancer research, subcutaneous and orthotopic, depending on the location of the implanted xenograft. Orthotopic tumor xenografts are increasingly being recognized for increased clinical relevance and explored accordingly.

An ideal imaging modality and reagent for diagnosis of pancreatic tumors remains elusive. In recent years, positron emission tomography (PET) using ¹⁸F-fluoro-2-deoxy-D-glucose (¹⁸F-FDG) has been most commonly used for the evaluation of pancreatic cancer, as in the other clinical settings of various cancers.⁴ However, certain pitfalls, including false-positive findings due to pancreatitis or false-negative diagnosis in hyperglycemic patients, limit the accuracy of detection.⁵ The availability of a more disease-specific imaging agent targeting tissue biomarkers of pancreatic carcinoma would overcome the shortcomings of metabolic probes.

Integrins are a family of adhesion molecules that mediate cell–cell and cell–extracellular matrix interactions and contribute to angiogenesis.⁶ Integrins regulate diverse functions in tumor cells, including adhesion, migration, invasion, proliferation, survival, and metastasis.⁷ The α_vβ₃ integrin, one of the most widely studied and well-characterized integrins, is highly expressed on proliferating endothelial cells during angiogenesis,⁸ as well as on cancer cells of various origins.⁹ Hosotani and colleagues examined the expression of α_vβ₃ integrin in human pancreatic cancer samples by immunohistochemical (IHC) analysis and reported that α_vβ₃ integrin was expressed in 58% of invasive pancreatic ductal carcinomas.¹⁰ Hence, α_vβ₃ integrin would be a good target, and PET imaging using a radiolabeled α_vβ₃ integrin tracer has the possibility to be a measure for the diagnosis of pancreatic cancer.

Radiolabeled cyclic peptides containing the Arg-Gly-Asp (RGD) amino acid sequence are commonly used as α_vβ₃ integrin imaging probes.^11,12 Our group has developed a PET imaging probe, ⁶⁴Cu-labeled cyclam-RAFT-c(-RGDfK-)₄, encompassing a cluster of four RGD peptides (designated ⁶⁴Cu-RAFT-RGD), for visualization and quantification of α_vβ₃ integrin expression in some animal tumor models. A tetrameric cRGD-containing peptide, known as RAFT-c(-RGDfK-)4, was synthesized by separately grafting four cyclo(-RGDfK-) monomers onto the upper side of the cyclic regioselectively addressable functionalized template (RAFT) decapeptide platform,¹³ conjugated with a bifunctional chelator, 1,4,8,11-tetraazacyclotetradecane (cyclam), and then radiolabeled with the positron emitter ⁶⁴Cu^14–16 (Figure 1).

Figure 1.

Molecular structure of ⁶⁴Cu-RAFT-RGD.

The purpose of the present study was to develop a clinically relevant orthotopic xenotransplantation model of pancreatic cancer that reflects the clinical situation and to perform preclinical evaluation of the diagnostic PET imaging probe ⁶⁴Cu-RAFT-RGD, allowed in this model. Previously, we used the subcutaneous models derived from stable transfectants of human embryonic kidney HEK293 cell lines (HEK293(β₁), HEK293(β₃)), overexpressing integrin β₁ and β₃ subunits, respectively, and human glioblastoma cell line U87 MG. Evaluation of ⁶⁴Cu-RAFT-RGD in an orthotopic tumor model derived from pancreatic cancer cell lines that have endogenous integrin expression has not been examined yet. We investigated integrin (α_vβ₃ and α_v) expression in pancreatic cancer cell lines, establishment of orthotopic pancreatic xenograft tumors, α_vβ₃ integrin–specific accumulation of ⁶⁴Cu-RAFT-RGD in tumors, lesion visualization by microPET/contrast-enhanced computed tomography (CECT) with comparison to ¹⁸F-FDG PET, and the validation of ⁶⁴Cu-RAFT-RGD uptake in tumor by autoradiography (ARG), histologic, and IHC examinations.

Materials and Methods

Cell Culture and Reagents

The human pancreatic cancer cell lines BxPC-3, MIAPaCa-2, AsPC-1, and PANC-1 and the human glioblastoma cell line U87MG were purchased from American Type Culture Collection (Manassas, VA). BxPC-3-RFP expressing red fluorescent protein (RFP; DsRed2) was purchased from AntiCancer, Inc. (San Diego, CA). All cell lines except MIAPaCa-2 and PANC-1 were cultivated at 37°C in a humidified atmosphere containing 5% CO₂ in RPMI 1640 medium (Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (Nichirei Biosciences, Tokyo, Japan), 100 U/mL penicillin-G sodium, and 100 mg/mL streptomycin sulfate (Invitrogen, Carlsbad, CA). Dulbecco's Modified Eagle's Medium was used for cultivation of MIAPaCa-2 and PANC-1 cell lines.

Flow Cytometric Analysis of Cellular α_vβ₃ Expression Level

Cellular α_vβ₃ integrin expression levels were measured using R-phycoerythrin-conjugated antihuman integrin α_vβ₃ monoclonal antibody (MAB1976H) (Chemicon, Temecula, CA). Incubation of cells with conjugated antibody was performed for 30 minutes at 4°C on cell suspensions in phosphate-buffered saline (PBS) containing 1% bovine serum albumin, 1 mM CaCl₂, and 1 mM MgCl₂. Cells were rinsed with PBS for flow cytometric analysis using Guava EasyCyte Plus Systems (Guava Technologies-Millipore, Hayward, CA). Cells treated with PBS without antibody were used as the negative control.

Western Blot Analysis

Western blotting (WB) was performed to analyze α_v integrin expression in both cultured cells and tissues samples. Whole-cell lysates were prepared using RIPA buffer (Wako Pure Chemical Industries, Osaka, Japan) with protease inhibitor cocktail (PIC) (Sigma-Aldrich, St. Louis, MO). Tumor tissue and normal pancreatic tissue were homogenized using tissue protein lysis reagent (CelLytic MT) with PIC. The amount of total protein was measured using the Nanodrop spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE). Protein (50 μg) was separated on a 10%polyacrylamide gel (ATTO Corporation, Tokyo, Japan) and transferred to Immobilon-P membrane (Millipore, Billerica, MA). The membrane was blocked with Block-Ace reagent (Dainippon Pharmaceutical, Osaka, Japan) at room temperature for 1 hour and incubated with primary antibody at room temperature for 1 hour. Rabbit antihuman integrin α_v (CD51) polyclonal antibody (Millipore, Temecula, CA) and goat antihuman actin (C-11) antibody (Santa Cruz Biotechnology, Santa Cruz, CA) were used. The membrane was washed with Tris-buffered saline (TBS) and incubated with the appropriate secondary antibody, which was a horseradish peroxidase (HRP)-linked donkey antirabbit or antigoat IgG (GE Healthcare, Little Chalfont, UK; Santa Cruz Biotechnology). Immunoreactive bands were visualized using the Enhanced Chemiluminescence Plus Western blotting detection system (GE Healthcare).

Development of an Orthotopic Pancreatic Cancer Xenograft Model in Mouse

All animal experiments were carried out in accordance with the guidelines for animal experimentation determined by the Animal Care and Use Committee at our institution. At first, BxPC-3-RFP cells (5 × 10⁶) were mixed with BD Matrigel Matrix (BD Biosciences, Bedford, MA) and subcutaneously inoculated into the flank of nude mice (8-week-old female BALB/cA Jcl-nu/nu mice, CLEA, Japan). When subcutaneous tumors had reached a size of 10 mm in longest diameter, the tumors were harvested and minced with scissors into 2 mm³ pieces in cold normal saline. We performed the surgical orthotopic implantation (SOI) under a 7× magnification LG-PS2 microscope (Olympus Corp., Tokyo, Japan). Under anesthesia, the recipient mouse abdomens were opened by left upper abdominal paramedian incision, and the pancreatic tail with the spleen was gently exteriorized. One donor tumor fragment was stitched into the pancreatic tail using 5-0 absorbable surgical suture (Akiyama Medical, Tokyo, Japan). The organs were then returned to the peritoneal cavity, and the abdominal wall and skin were closed in two layers with surgical suture. The SOI recipient mice were monitored and weighed daily to check for any signs of stress, trauma, or surgical complication.

In Vivo Fluorescence Imaging to Confirm Establishment of the Implanted Tumor

To identify the development of BxPC-3-RFP orthotopic tumors, in vivo fluorescence imaging of recipient mice was conducted every 3 to 4 days by using the IVIS Lumina optical imaging system (Xenogen Corp., Alameda, CA). A filter set for DsRed and constant imaging parameters (exposure time: 1 second; binning: medium; lens aperture [f/stop]: 1; field of view [FOV]: 12.5 cm; floor lamp level: high) were used. Gross dissected specimen of orthotopic tumor was reconfirmed by an MZ16F stereo fluorescence microscope (Leica Microsystem, Wetzlar, Germany).

Peptide Synthesis and Labeling

Cyclam-RAFT-c(-RGDfK-)₄ peptide and radiolabeling with ⁶⁴Cu were performed according to our previously described method.^14–16 The radiochemical purity and specific radioactivity of ⁶⁴Cu-RAFTRGD used in the present study were > 98% and ≈ 18.5 MBq/nmol, respectively.

In Vivo Radiolabeled Peptide Biodistribution and Receptor-Blocking Studies

Mice bearing orthotopic pancreatic tumors were divided into two groups, blocking and nonblocking (n = 3 for each group). Mice of the nonblocking group were intravenously injected with ⁶⁴Cu-RAFT-RGD (0.37 MBq) via the tail vein, and the blocking group received coinjection with an excessive amount of unlabeled peptide (150 nmol/200 μL) according to the previously reported technique.¹⁵ Two hours after injection, the mice were sacrificed, each tissue of interest was excised, and the radioactivities were measured by a gamma-counter. Radioactivity uptake was expressed as a percentage of injected dose per gram of tissue (%ID/g) normalized to a 20 g mouse body weight.

PET Imaging Coregistered with CECT

Mice bearing orthotopic pancreatic tumors were intravenously injected with 7.4 MBq of ⁶⁴Cu-RAFT-RGD. Two hours after injection, static PET data acquisition was conducted for 30 minutes using a small-animal PET system (Inveon, Siemens Medical Solutions, Malvern, PA) under 1.5% isoflurane anesthesia. Images were reconstructed using a maximum a posteriori reconstruction method with attenuation correction and Inveon Acquisition Workplace software (Siemens Medical Solutions). To obtain the relevant anatomic information, mice fixed in the same bed position were moved to the in vivo micro x-ray computed tomographic (CT) system R_mCT2 (Rigaku Co., Tokyo) scanner immediately after PET scanning. There the mice were intravenously injected with 200 μL of Iopamiron 370 contrast medium (Nihon Schering, Osaka, Japan), and CECT imaging was conducted 20 minutes after injection. The whole-body image was taken with an exposure time of 2 minutes, tube voltage of 90 kV, a current of 200 μA, and an FOV of 60 mm in diameter. Images were obtained with the image reconstruction, visualization, and analysis program provided by the manufacturer. For comparison of ¹⁸F-FDG and ⁶⁴Cu-RAFT-RGD, mice underwent a continuous 2-day imaging protocol with ¹⁸F-FDG PET on day 1 and ⁶⁴Cu-RAFT-RGD PET on day 2. After overnight fasting, mice were intravenously injected with ¹⁸F-FDG (3.7 MBq). Fifty minutes after injection, static PET data acquisition was conducted for 10 minutes and CECT was also performed for all mice. Both the PET and CECT data sets were coregistered to confirm the anatomic location of tumors, and fused images were obtained using PMOD PET data analysis software (PMOD Technologies, Zurich, Switzerland). Using ASIPro VM software (CTI Concorde Microsystems, Knoxville, TN), regions of interest (ROI) were manually drawn on three slices in three planes (coronal, transverse, sagittal) of each tumor, and the mean standardized uptake value (SUV_mean) was measured in each ROI for quantitative analysis.

Postimaging Ex Vivo Autoradiography, Histologic Examination, and IHC and Immunofluorescence Staining

After ⁶⁴Cu-RAFT-RGD PET imaging, the mouse was sacrificed, and the tumor with surrounding normal pancreatic tissue was removed, embedded in Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA), and frozen by immersion in n-hexane precooled at −80°C. Frozen sections were serially cut into 10 μm thickness for ARG and hematoxylin-eosin (HE), IHC, and immunofluorescence (IF) staining. Tracer ARG was acquired by exposing the frozen sections to an imaging plate (BAS-MS 2040, Fujifilms Co. Ltd., Tokyo, Japan) in a freezer overnight. The imaging plate was scanned with an FLA-7000 bioimaging analyzer (Fujifilms Co. Ltd.), and the serial sections were stained with HE for histologic examination. For IHC staining, sections were fixed in acetone and incubated with mouse antihuman integrin α_vβ₃ monoclonal primary antibody (MAB1976) (Millipore, Temecula, CA). EnVivion⁺ HRP-labeled polymer antimouse antibody (Dako, Glostrup, Denmark) was used as a secondary antibody. Then the sections were stained with diaminobenzidine (Dako) and nuclei were counterstained with hematoxylin. For IF staining of microvessels, rat antimouse CD31 monoclonal antibody (BD Biosciences) and Alexa Fluor 594–conjugated goat antirat secondary antibody (Invitrogen) were used. Images were acquired with an epifluorescence microscope (Olympus X61) equipped with an imaging tiling system (e-Tiling, Mitani Corporation, Fukui, Japan).

Statistical Analysis

Significant differences between groups were determined by Student t-test, and p values < .05 were considered significant.

Results

α_vβ₃ Integrin Expression in Human Pancreatic Cancer Cell Lines

Four human pancreatic cancer cell lines were examined by flow cytometry for α_vβ₃ expression (Figure 2, A and B). For reference, the human glioblastoma cell line U87MG, reported for its high endogenous α_vβ₃ expression, was used as a positive control. BxPC-3 and PANC-1 showed high α_vβ₃ expression levels comparable to those of the positive control. MIAPaCa-2 and AsPC-1 showed relatively low expression of α_vβ₃. The α_v expression levels in respective cell lysates in WB analysis were concordant with α_vβ₃ expression measured with flow cytometry (Figure 2C). With WB analysis, the BxPC-3-RFP cell line demonstrated an α_v expression level equivalent to that of BxPC-3, and BxPC-3-RFP tumor tissue lysate also demonstrated α_v expression.

Figure 2.

A, Flow cytometric analysis of α_vβ₃ integrin expression in four human pancreatic cancer cell lines. Human glioblastoma cell line U87MG was used as the positive reference. The representative results of two experiments are shown. B, Numbers in the upper-right quadrant indicate the percentage of cells that were α_vβ₃ positive, shown with a bar graph. C, With Western blotting, α_v integrin expression in cell lysates of U87MG (lane 1), MIAPaCa-2 (lane 2), AsPC-1 (lane 3), PANC-1 (lane 4), BxPC-3 (lane 5), and BxPC-3-RFP (lane 6) were detected. Tissue lysates of BxPC-3-RFP tumor (lanes 7 and 9) showed α_v integrin expression. Mouse normal pancreatic tissues were used as a negative control (lanes 8 and 10).

Establishment of an Orthotopic Pancreatic Cancer Xenograft Model Using SOI

As shown in Figure 3A, we performed the SOI to establish transplanted tumor. At 3 to 6 days after SOI, most of the mice showed enhanced fluorescence activity in the tumor-implanted site, indicating the existence of tumor. After 18 days, all mice had orthotopic xenografts observed by in vivo fluorescence imaging (Figure 3B). The tumor take rate of SOI was 100% in our model.

Figure 3.

A, Intraoperative photographs of the surgical orthotopic implantation (SOI) procedure. B, In vivo fluorescence image confirmed the establishment of implanted tumor 6 days after SOI. peri = peritoneum.

Biodistribution and Receptor-Blocking Studies

The biodistribution of ⁶⁴Cu-RAFT-RGD was examined in mice bearing BxPC-3-RFP orthotopic tumors 2 hours after intravenous injection (Figure 4), and the blood radioactivity was as low as 0.14 ± 0.04 %ID/g, indicating rapid blood clearance. Radioactivity in orthotopic pancreatic tumor was 6.01 ± 0.75 %ID/g, and surrounding normal pancreatic tissue uptake was 0.88 ± 0.17 %ID/g. Radioactivity accumulation in the kidney was as high as 15.79 ± 2.43 %ID/g, indicating prominent renal excretion of the probe. Moderate liver uptake of 5.38 ± 0.04 %ID/g was seen. Radioactivity accumulation in other tissues was low or negligible. Heart, lung, spleen, stomach, small intestine, muscle, and bone showed uptake of 0.95 ± 0.13, 2.70 ± 1.13, 3.41 ± 0.38, 2.40 ± 0.64, 2.50 ± 0.19, 0.65 ± 0.08, and 1.28 ± 0.20 %ID/g, respectively (Table S1, available online only). The tumor to blood, tumor to muscle, tumor to pancreas, and tumor to liver ratios were 46.64 ± 9.93, 9.3 ± 0.25, 7.11 ± 2.17, and 1.12 ± 0.15, respectively (see Figure 4B). The binding specificity of ⁶⁴Cu-RAFTRGD was validated by coinjection with an excessive amount of unlabeled peptide. As demonstrated in Figure 4, a significant decrease, 95.5%, in radioactivity was achieved in tumors after blocking (see Figure 4A). All other examined tissues (except kidney, lung, and spleen) showed significant reduction as well.

Figure 4.

A, Biodistribution of ⁶⁴Cu-RAFT-RGD in nude mice bearing a BxPC-3-RFP orthotopic tumor 2 hours after receiving ⁶⁴Cu-RAFT-RGD injection alone (gray) or coinjection with an excessive amount of unlabeled probe (black). B, 0.1 X Tumor to blood, tumor to muscle, tumor to pancreas, and tumor to liver ratios were compared. Data are represented as mean ± SD (n = 3 for each group) (*p < .05).

MicroPET/CECT

Static PET scans followed by CECT were undertaken. CECT images of mice delineated the tumor and depicted the surrounding nontumor tissues, such as liver, stomach, intestine, and kidneys (Figure 5, B and E). Images showing tumor and whole-body uptake of radioactivity 2 hours after ⁶⁴Cu-RAFT-RGD injection (Figure 5A) and 50 minutes after ¹⁸F-FDG injection (Figure 5D) were compared. Coregistered and superimposed PET images on CECT images facilitated precise and easy detection of pancreatic cancer lesions (Figure 5, C and F). In addition, tracer uptake by nontumor tissues could be distinctly identified on fusion images. Tumor was clearly visualized by high ⁶⁴Cu-RAFT-RGD accumulation, giving good contrast. ¹⁸F-FDG uptake in tumor seemed to be low, with poor contrast. By quantifying the tumor uptake, the SUV_mean for ⁶⁴Cu-RAFT-RGD tended to be higher than that for ¹⁸F-FDG (0.48 ± 0.19 vs 0.34 ± 0.06), although not statistically significant (Figure 5G), with a p value of .081.

Figure 5.

MicroPET/CECT images (coronal and transverse) of a representative mouse bearing an orthotopic pancreatic tumor. Images of the upper panel (A, B, and C) were obtained 2 hours after injection of ⁶⁴Cu-RAFT-RGD. Images of the lower panel (D, E, and F) were obtained 50 minutes after injection of ¹⁸F-FDG in the same mouse 1 day before ⁶⁴Cu-RAFT-RGD PET. The fusion images (C and F) obtained by superimposing of PET images (A and D) on corresponding CECT images (B and E) indicated marked tumor to background contrast and slightly higher uptake of ⁶⁴Cu-RAFT-RGD compared to ¹⁸F-FDG in tumor lesions (arrowhead). G, Tumor ⁶⁴Cu-RAFT-RGD and ¹⁸F-FDG uptake (SUV_mean) were compared. Data are represented as mean ± SD (n = 6 for ⁶⁴Cu-RAFT-RGD and n = 8 for ¹⁸F-FDG) (p = .081).

Validation by Ex Vivo ARG, Histologic, IHC, and IF Examinations

Immediately after PET imaging, mice were euthanized and the abdominal wall was opened to inspect the pancreatic cancer lesion macroscopically. The position of gross tumor (Figure 6D) was identical to that of the region of high tracer uptake seen in ⁶⁴Cu-RAFT-RGD PET (Figure 6C) and enhanced fluorescence activity seen on in vivo fluorescence imaging (Figure 6B). Gross specimens of tumor with surrounding normal pancreatic tissue (Figure 6E) were removed and processed for ARG and HE, IHC, and IF staining. On ARG images, high ⁶⁴Cu-RAFT-RGD accumulation was observed in tumor but not in normal pancreas (Figure 6F). HE staining of adjacent sections showed clear a histopathologic difference between tumor and normal pancreatic acinar cells (Figure 6G). The tumor area exhibited neoplastic cells with high-grade nuclear features (pleomorphic nuclei, prominent nuclei) and some regions of desmoplasia, which are characteristic of human pancreatic cancer. With the IHC staining, α_vβ₃ integrin expression in tumor cells and their inhomogeneous distribution in tumor area, compared to normal pancreatic acinar cells, were observed (Figure 6I). CD31 IF staining revealed that that there was no abundant tumor microvascular network over the normal area, indicating that our pancreatic tumor had less vascularity compared to the common feature of other vascular-rich tumors (Figure 6H).

Figure 6.

A, White light image and fluorescence image of gross dissected specimen. Optical (B), PET (C), and dissected (D) whole-body specimen images from a representative mouse bearing an orthotopic pancreatic tumor (arrowhead). E, Gross specimen of tumor and normal pancreatic tissue excised from this mouse. F, Tumor area showed high radioactivity on ex vivo autoradiographic (ARG) image. G, Adjacent section was stained with hematoxylin and eosin (HE), and histopathology was observed with low- (X4) and high-power magnification (X20). HE staining demonstrated neoplastic cells with high-grade nuclear features and some regions of desmoplasia in the tumor area and normal acinar cells in pancreatic parenchyma. H, CD31 immunostaining of the serial section indicated unabundant vascularity in the tumor area. I, Enhanced immunohistochemical (IHC) staining of α_vβ₃ integrin in tumor cells but not in normal acinar cells was visualized with low- (X4) and high-power magnification (X20). I = intestine; IF = immunofluorescence; N = normal pancreatic tissue; S = spleen; T = tumor.

Discussion

Compared to some limitations of the subcutaneous model, orthotopic pancreatic tumor more closely mimics the natural biologic behavior and characteristics of human pancreatic cancer because it grows in its native micro-enviroment and reliably replicates certain important characteristics of human malignancy, such as local invasion and metastasis.¹⁷ Therefore, the orthotopic tumor model is more suitable for examination of the tumor–host interactions directing disease-relevant metastases and loco-regional growth, the tumor site–dependent therapeutic response, and specific gene expression in target organs and tumor. On the other hand, some drawbacks exist in the generation of an orthotopic tumor model, which is time and labor consuming and demands skilled work, high cost, longer healing and recovery time after surgery, and limited throughput because of imaging methods that are necessary to monitor the tumor. Nevertheless, orthotopic tumor models are emerging as the preference for pancreatic cancer research due to the greater clinical relevance.¹⁸ There are a variety of techniques to generate an orthotopic pancreatic cancer model in immunodeficient mice, such as direct injection of tumor cells into the pancreas with or without Matrigel,^19,20 and surgical transplantation of a small tumor fragment derived from subcutaneous tumors in donor animals²¹ or directly from patient specimens²² has also been reported by several groups. In this study, we established orthotopic pancreatic cancer models in recipient nude mice by the SOI method and investigated the possibility of accurate detection of this cancer using this model and the PET imaging agent ⁶⁴Cu-RAFT-RGD. We used the human pancreatic cancer cell line BxPC-3-RFP with stable and high expression of RFP, which could easily be monitored with an optical imaging system and facilitated real-time visualization of tumor development inside the abdomen. Tumor growth at the implanted site was visible a few days following operation, and tumor became visible in all recipient mice within 18 days, exhibiting a 100% tumor take rate in our experiment (see Figure 3). The main beneficial characters of SOI were rapid, and predictable tumor growth and feasibility to avoid undesired peritoneal spread and carcinomatosis occurred by leakage of cell suspension in a direct injection method, which was used to form a traditional orthotopic model. Moreover, with the difference from the subcutaneous model, orthotopic tumor invasion to surrounding organs such as the small intestine, stomach, liver, spleen, and peritoneum was noticed in some cases. Metastases to distant organs were not evaluated in this work.

On the clinical front, the best option for pancreatic cancer treatment is curative surgery, and timely detection of lesions is critically important. In current practice, ¹⁸F-FDG-PET imaging has been widely applied as a noninvasive, functional imaging technique using ¹⁸F-FDG to characterize the enhanced glucose use of cancer cells for detection, staging, monitoring treatment response, and finding recurrence of various malignant diseases, including pancreatic cancer.²³ Still, no conclusive consensus has been reached with regard to whether the role of ¹⁸F-FDG-PET is crucial in pancreatic cancer management.²⁴ According to the literature, despite the finding that 18F-FDG-PET is useful in the management of pancreatic cancer, it is not regarded as an ideal method because ¹⁸F-FDG uptake can overlap in benign and malignant diseases and not provide high enough diagnostic accuracy for malignant pancreatic tumors in some cases,²⁵ and it has a limited role in the evaluation of metastasis.²⁶ False-positive findings due to nonspecific ¹⁸F-FDG uptake by several benign conditions, such as inflammatory disease, granulomatous disease, and gastrointestinal, muscle, and brown fat uptake, and false negative results due to high blood glucose levels in patients or low glucose transporter protein and glucose phosphorylation enzyme expression in indolent tumors are major flaws of ¹⁸F-FDG. In light of this fact, a more disease-specific imaging probe that targets specific molecular or genetic abnormalities of disease, rather than depending only on metabolic changes, would be a desirable probe for tumor detection.

To visualize the tumor with a targeted imaging approach, an adequate level of accessible tumor-specific target is important to detect and delineate lesions from background. α_vβ₃ Integrin, the most actively studied of the integrins, serves as an excellent molecular target for tumor imaging because it is not readily detectable in quiescent vessels but becomes highly expressed in proliferating tumor vasculature⁶ and in tumor cells themselves. High α_vβ₃ integrin expression in many types of carcinoma, such as glioma²⁷; melanoma²⁸; breast,²⁹ ovarian,³⁰ lung,³¹ and colon³² cancer; and squamous cell carcinoma of head and neck³³ has been reported, whereas its expression in corresponding normal tissue is low or absent. The ability to noninvasively visualize and quantify α_vβ₃ integrin expression levels can provide an outlook to verify the presence of tumor cells themselves along with sprouting surrounding tumor vasculature. As with certain other malignant tumors, α_vβ₃ integrin is often highly expressed in pancreatic cancer cells,¹⁰ whereas it is hardly expressed in normal pancreatic cells. Concordantly, our flow cytometric analysis exhibited high expression of α_vβ₃ integrin in BxPC-3 and PANC-1 pancreatic cancer cell lines and relatively low levels in MIAPaCa-2 and AsPC-1 lines (see Figure 2, A and B). The observation of α_vβ₃ integrin expression in other varieties of pancreatic cancer cell lines in future studies should improve the consensus. The α_v integrin subunit expression in corresponding cell lysates seen in our WB analysis was also consistent with α_vβ₃ integrin expression measured with flow cytometry (see Figure 2C). The BxPC-3-RFP that we used as a cell line for the orthotopic model and PET experiments had almost identical α_v integrin expression level as BxPC-3. In addition, BxPC-3-RFP tumor tissue lysate revealed av integrin expression on protein blot. Our IHC examination also described the increased α_vβ₃ integrin expression in cells of tumor frozen section, and it was concordant with the WB result. Thus, visualization of pancreatic cancer using α_vβ₃-targeted radiolabeled RGD peptides can be expected. We previously compared the cell binding of ⁶⁴Cu-RAFT-RGD peptide using monolayer cultured of HEK293(β₁) and HEK293(β₃) cell lines. The binding activity that was expressed as the cell-bound radioactivity in percentage of totally added radioactivity normalized to 100 μg of protein were 0.34 ± 0.04% and 15.67 ± 0.74%, which indicated good binding of ⁶⁴Cu-RAFT-RGD for α_vβ₃. Moreover, we also studied the feasibility of selectively imaging α_vβ₃ integrin–expressing tumors in vivo,¹⁶ as well as tumor angiogenesis integrated by α_vβ₃-expressing activated endothelial cells during angiogenesis³⁴ using the ⁶⁴Cu-RAFT-RGD PET probe. Furthermore, we reported high ⁶⁴Cu labeling efficiency for cyclam conjugate¹⁵ and achieved a ⁶⁴Cu-RAFT-RGD probe with favorable pharmacokinetics in terms of biostability, quick blood clearance with prevailing renal excretion, high specificity, and strong affinity to α_vβ₃ integrin expression.^16,34 As an extension to these achievements, in the present study, we sought to evaluate the potential use of ⁶⁴Cu-RAFT-RGD for pancreatic cancer detection. The α_vβ₃ integrin–targeted specificity of ⁶⁴Cu-RAFT-RGD was assessed by means of an in vivo radiolabeled probe biodistribution with receptor blocking study, and, in good agreement with the previous report, in vivo α_vβ₃-binding specificity of ⁶⁴Cu-RAFT-RGD was validated by coinjection with an excessive amount of unlabeled probe. ⁶⁴Cu-RAFT-RGD accumulation was significantly diminished by blocking probe, which produced a 95.5% reduction in ⁶⁴Cu-RAFT-RGD accumulation in tumor and certain reductions in other tissues and demonstrated the α_vβ₃-specific binding character of RGD targeted to inherent high and basal α_vβ₃ integrin expression of tumor and nontumor tissues (see Figure 4, A and B).

As imaging probes become more specific regarding successful measurable uptake in only the tumor or other tissue, it is important to depict the exact anatomic location of the uptake. Many studies have shown that by combining anatomic and functional imaging techniques, PET/CT images surpass either PET, CT, or PET and CT images viewed side by side.³⁵ Generally, PET depends on biochemical or molecular characteristics of diseases and may yield unsatisfactory resolution of the image, whereas CT affords morphology and structure of diseased organs with very high spatial resolution. Thus, by precise coregistration of PET and CT, synergistic and complementary effects may be expected to increase the specificity, sensitivity, and interpretation of PET and indentification of organ underlying probe accumulation. In the present study, we performed PET and CECT and coregistered for a single set of fused images. Through PET/CECT fusion images of three planes, coronal, transverse, and sagittal, we could identify the location of tumor and surrounding organs, which were relatively clearly visualized on CECT. Even tumors that were closely located to kidney and liver and somewhat hard to delineate due to high renal or moderate liver uptake of ⁶⁴Cu-RAFT-RGD in PET images alone were successfully recognized on fusion images. Together with CECT, ⁶⁴Cu-RAFT-RGD PET apparently demonstrated 100% of all implanted orthotopic pancreatic tumors in the present study.

We also evaluated ⁶⁴Cu-RAFT-RGD and ¹⁸F-FDG uptake 2 hours and 50 minutes after injection, respectively. These time points were known and suitable to obtain satisfactory contrast between tumor and nontumor tissues according to our preliminary experimental experience. When the PET images of the two radiotracers were compared, the ⁶⁴Cu-RAFT-RGD PET gave a much better tumor to background contrast (see Figure 5, A–F) and slightly higher tumor uptake compared to ¹⁸F-FDG (see Figure 5G).

Additionally, our postimaging ARG, histopathologic, and IHC examinations supported the potential of ⁶⁴Cu-RAFT-RGD PET for imaging of pancreatic cancer because a probe accumulation difference between tumor and surrounding normal pancreatic tissue was clearly found in ARG (see Figure 6F) and was confirmed by HE (see Figure 6G) and IHC (see Figure 6I) staining of adjacent sections. Taken together, the overall results of our model study have demonstrated that α_vβ₃ integrin–targeted imaging using ⁶⁴Cu-RAFT-RGD can function as a highly specific imaging tool for pancreatic cancer, visibly distinguishing it from adjacent normal tissues. Generally, human pancreatic cancer is relatively hypovascular in nature compared to the other tumors known for rich vascular supply.³⁶ We also found a relatively poor microvessel network in tumor by IF detection method for panendothelial cell marker CD31 using antimouse monoclonal antibody (see Figure 6H). Hence, ⁶⁴Cu-RAFT-RGD accumulation in our tumor model might be predominantly associated with α_vβ₃ integrin expression of tumor cells themselves rather than its expression on activated endothelial cells.

Recently, Yoshimoto and colleagues reported that single-photon emission computed tomography (SPECT) with ¹¹¹In-DOTA-c(RGDfK) has great potential for the early diagnosis of pancreatic cancer in the hamster carcinogenesis model by showing specific uptake in tumor but not in inflammatory lesions and normal pancreas.³⁷ They used a monomeric RGD peptide that has been reported by other groups as causing high radioactivity accumulation in the liver and intestine due to its unfavorable hepatobiliary pathway.³⁸ Now, multimerization of RGD peptides is the trend in the development of RGD peptides to enhance binding affinity and specificity for α_vβ₃ integrin, leading to high tumor accumulation and retention in the tumor.³⁹ Our tetrameric RGD-based peptide fulfilled these properties, and its high renal accumulation could be reduced by pre- or coinjection with the plasma expander gelofusine.⁴⁰ With PET advantages in terms of detection sensitivity and image resolution over SPECT, we anticipate that ⁶⁴Cu-RAFT-RGD will be a more preferable probe.

Although further translational studies in humans will be needed, the high-quality performance of present-day clinical PET in terms of spatial resolution and hybrid PET/CT technologies should provide clinical use of ⁶⁴Cu-RAFT-RGD in the management of pancreatic cancer in the near future. According to the radiochemical properties of the labeled isotope ⁶⁴Cu (half-life 12.7 hours; β⁺ 19%; E_β+max 0.655 MeV; β⁻ 40%; E_β–max 0.573 MeV) and its feasibility of production via a small biomedical cyclotron,⁴¹ along with the possibility of reduced risk of nephrotoxicity by coinjection of gelofusine, ⁶⁴Cu-RAFT-RGD should be an attractive and favorable probe for diagnostic PET imaging and internal radiotherapy of pancreatic cancer, which is another interesting subject of the research that should be performed in the future.

Conclusion

The present study on an orthotopic xenotransplantation model in mouse and the comprehensive results suggest that the targeted molecular probe ⁶⁴Cu-RAFT-RGD possesses specific binding to α_vβ₃ integrin of pancreatic tumor cells, may provide higher detectability over ¹⁸F-FDG-PET, and might be a potentially applicable candidate for the diagnosis of pancreatic cancer expressing α_vβ₃ integrin.

Footnotes

Acknowledgments

We thank Hisashi Suzuki and other members of the Molecular Probe Program for ⁶⁴Cu production; the Cyclotron Operation Section for cyclotron operation; all members of the Diagnostic Imaging Program, Molecular Imaging Center, National Institute of Radiological Sciences, and Dr. Jean-Luc Coll of INSERM U823, Institut Albert Bonniot, Université Joseph Fourier, Grenoble, France, for helpful discussion.

Financial disclosure of authors: This study was partly supported by a Grant-in-Aid for Scientific Research (C) (24591804) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Financial disclosure of reviewers: None reported.

References

Hariharan

Saied

Kocher

. Analysis of mortality rates for pancreatic cancer across the world. HPB 2008;10:58–62, doi: 10.1080/13651820701883148.

Siegel

Naishadham

Jemal

. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29, doi:10.3322/caac.20138.

Killion

Radinsky

Fidler

. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998;17:279–84, doi:10.1023/A:1006140513233.

Sendler

Avril

Helmberger

. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 2000;24:1121–9, doi:10.1007/s002680010182.

Shreve

. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998;25:259–64, doi:10.1007/s002590050226.

Brooks

Clark

Cheresh

. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569–71, doi:10.1126/science.7512751.

Desgrosellier

Cheresh

. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9–22, doi:10.1038/nrc2748.

Stromblad

Cheresh

. Integrins, angiogenesis and vascular cell survival. Chem Biol 1996;3:881–5, doi:10.1016/S1074-5521(96)90176-3.

Mizejewski

. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999;222:124–38, doi:10.1046/j.1525-1373.1999.d01-122.x.

10.

Hosotani

Kawaguchi

Masui

. Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis. Pancreas 2002;25:e30–5, doi:10.1097/00006676-200208000-00021.

11.

Haubner

Wester

Weber

. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781–5.

12.

Zhang

Xiong

. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med 2006;47:113–21.

13.

Boturyn

Coll

Garanger

. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J Am Chem Soc 2004;126:5730–9, doi:10.1021/ja049926n.

14.

Galibert

Dumy

Boturyn

. One-pot approach to well-defined biomolecular assemblies by orthogonal chemoselective ligations. Angew Chem Int Ed Engl 2009;48:2576–9, doi:10.1002/anie.200806223.

15.

Galibert

Jin

Furukawa

. RGD-cyclam conjugate: synthesis and potential application for positron emission tomography. Bioorg Med Chem Lett 2010;20:5422–5, doi:10.1016/j.bmcl.2010.07.114.

16.

Jin

Furukawa

Galibert

. Noninvasive visualization and quantification of tumor alphaVbeta3 integrin expression using a novel positron emission tomography probe, 64Cu-cyclam-RAFT-c(-RGDfK-)4. Nucl Med Biol 2011;38:529–40, doi:10.1016/j.nucmedbio.2010.11.008.

17.

Bouvet

Hoffman

. Clinically-relevent orthotopic metastatic models of pancreatic cancer imageable with fluorescent genetic reporters. Minerva Chir 2009;64:521–39.

18.

Huynh

Abrahams

Torres

. Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells. Plos One 2011;6:e20330, doi:10.1371/journal.pone.0020330.

19.

Evelhoch

Mohammad

. Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer. Pancreas 2000;21:69–76, doi:10.1097/00006676-200007000-00054.

20.

Partecke

Sendler

Kaeding

. A syngeneic orthotopic murine model of pancreatic adenocarcinoma in the C57/BL6 mouse using the Panc02 and 6606PDA cell lines. Eur Surg Res 2011;47:98–107, doi:10.1159/000329413.

21.

Katz

Takimoto

Spivack

. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. J Surg Res 2003;113:151–60, doi:10.1016/S0022-4804(03)00234-8.

22.

Cui

Kruger

Vogel

. Intact tissue of gastrointestinal cancer specimen orthotopically transplanted into nude mice. Hepatogastroenterology 1998;45:2087–96.

23.

van Kouwen

Oyen

Nagengast

. FDG-PET scanning in the diagnosis of gastrointestinal cancers. Scand J Gastroenterol Suppl 2004;241:85–92.

24.

Hustinx

. PET imaging in assessing gastrointestinal tumors. Radiol Clin North Am 2004;42:1123–39, ix, doi:10.1016/j.rcl.2004.08.003.

25.

Asagi

Ohta

Nasu

. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence. Pancreas 2013;42:11–9, doi:10.1097/MPA.0b013e3182550d77.

26.

Kim

Lee

. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer. Pancreas 2012;41:897–903, doi:10.1097/MPA.0b013e318252f4f5.

27.

Jia

Shi

Yang

. 99mTc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression. Bioconj Chem 2006;17:1069–76, doi:10.1021/bc060055b.

28.

Schmieder

Winter

Caruthers

. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med 2005;53:621–7, doi:10.1002/mrm.20391.

29.

Vellon

Menendez

Lupu

. AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene 2005;24:3759–73, doi:10.1038/sj.onc.1208452.

30.

Dijkgraaf

Kruijtzer

Frielink

. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer 2007;120:605–10, doi:10.1002/ijc.22297.

31.

Chen

Sievers

Hou

. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia 2005;7:271–9, doi:10.1593/neo.04538.

32.

Vonlaufen

Wiedle

Borisch

. Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod Pathol 2001;14:1126–32, doi:10.1038/modpathol.3880447.

33.

Beer

Grosu

Carlsen

. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6610–6, doi:10.1158/1078-0432.CCR-07-0528.

34.

Jin

Furukawa

Claron

. Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c(-RGDfK-)4. Angiogenesis 2012;15:569–80, doi:10.1007/s10456-012-9281-1.

35.

Nguyen

. ¹⁸F-FDG PET/CT imaging of the pancreas: spectrum of diseases. JOP 2011;12:557–66.

36.

Sofuni

Iijima

Moriyasu

. Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol 2005;40:518–25, doi:10.1007/s00535-005-1578-z.

37.

Yoshimoto

Hayakawa

Mutoh

. In vivo SPECT imaging with 111In-DOTA-c(RGDfK) to detect early pancreatic cancer in a hamster pancreatic carcinogenesis model. J Nucl Med 2012;53:765–71, doi:10.2967/jnumed.111.099630.

38.

Haubner

Wester

Reuning

. Radiolabeled alpha(v)-beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999;40:1061–71.

39.

Cai

Cao

. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 2007;48:1162–71, doi:10.2967/jnumed.107.039859.

40.

Briat

Wenk

Ahmadi

. Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin alphavbeta3 targeting using single photon emission computed tomography and optical imaging. Cancer Sci 2012;103:1105–10, doi:10.1111/j.1349-7006.2012.02286.x.

41.

Lewis

Cutler

. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res 1999;5:3608–16.

Micro–Positron Emission Tomography/Contrast-Enhanced Computed Tomography Imaging of Orthotopic Pancreatic Tumor–Bearing Mice Using the α v β 3 Integrin Tracer 64 Cu-Labeled Cyclam-RAFT-c(-RGDfK-) 4

Abstract

Materials and Methods

Cell Culture and Reagents

Flow Cytometric Analysis of Cellular αvβ3 Expression Level

Western Blot Analysis

Development of an Orthotopic Pancreatic Cancer Xenograft Model in Mouse

In Vivo Fluorescence Imaging to Confirm Establishment of the Implanted Tumor

Peptide Synthesis and Labeling

In Vivo Radiolabeled Peptide Biodistribution and Receptor-Blocking Studies

PET Imaging Coregistered with CECT

Postimaging Ex Vivo Autoradiography, Histologic Examination, and IHC and Immunofluorescence Staining

Statistical Analysis

Results

αvβ3 Integrin Expression in Human Pancreatic Cancer Cell Lines

Establishment of an Orthotopic Pancreatic Cancer Xenograft Model Using SOI

Biodistribution and Receptor-Blocking Studies

MicroPET/CECT

Validation by Ex Vivo ARG, Histologic, IHC, and IF Examinations

Discussion

Conclusion

Footnotes

Acknowledgments

References

Flow Cytometric Analysis of Cellular α_vβ₃ Expression Level

α_vβ₃ Integrin Expression in Human Pancreatic Cancer Cell Lines